24 related news articles for COVID-19

A young Melbourne scientist will spend the next three years advancing exiting new mRNA research to unlock the secrets to how RNA triggers the immune system to fight infection.…  Read more

A naturally occurring molecule found in soy products could hold the clue to a new class of potent anti-inflammatory drugs, targeting diseases ranging from heart conditions to COVID-19.…  Read more

Hudson Institute’s groundbreaking research into new anti-inflammatory treatments has attracted the support of the Victorian government, in recognition of its potential to treat COVID-19 and other infectious diseases.…  Read more

The enormous potential of RNA-based treatments for autoimmune diseases has been recognised by the Victorian government, with a new grant from the mRNA Victoria Research Acceleration Fund.…  Read more

RNA technology developed by Hudson Institute of Medical Research with the potential to limit inflammatory side-effects of RNA therapeutics such as mRNA vaccines, is the subject of a new licensing deal.…  Read more

Hudson Institute’s expertise in established and emerging fields of medical research has been recognised, with Research Group Head Dr Minni (Minna-Liisa) Änkö added to mRNA Victoria’s Scientific Advisory Group (SAG).…  Read more

A paper published in the prestigious journal, Science Immunology, explores the idea that studying bats’ responses to SARS-CoV-2 may provide key insights into how and when to best use existing therapies for COVID-19, and to develop new treatments.…  Read more

Dr Emily Camm named one of 17 STEM Ambassadors by Science and Technology Australia for 2021. …  Read more

Leading virus scientist, Associate Professor Michelle Tate explains why new treatments are needed alongside vaccines.…  Read more

Hudson Institute of Medical Research today welcomed the Victorian Government’s initial investment to kick-start a National Centre for Inflammation Research (NCIR) to be established at the Monash Health Translation Precinct (MHTP) in Melbourne’s growing south-eastern corridor.…  Read more

It is unknown how US President Donald Trump will respond to the experimental immunotherapy given to treat his COVID-19 infection, because the drug has not yet been tested and approved, says Hudson Institute Director and CEO, Professor Elizabeth Hartland.…  Read more

Hudson Institute scientists have discovered the key to how cells turn on inflammation and fight infection, providing the knowledge to potentially reduce or stop destructive inflammation in the future.…  Read more

Australia’s medical research sector will benefit from the appointment of Hudson Institute inflammation scientist Associate Professor Ashley Mansell to global firm Morningside BioPharma Advisory,…  Read more

Inflammation is at the core of life-threatening severe COVID-19 cases. More than 100 researchers at Hudson Institute investigate…  Read more

The first clinical trial of a potential COVID-19 treatment involving a discovery by Hudson Institute researchers received approval in September.…  Read more

Olive, 11 and her brother Will, 8 wanted to say a big thank you to their scientist heroes for all their hard work to improve people’s lives, including on COVID-19 research.…  Read more

My name is Michael Gantier and I am a scientist at Hudson Institute. My lab is working on a potential treatment for life-threatening COVID-19 symptoms, …  Read more

More than 200,000 people have died from COVID-19 since January 2020. While Australia has been relatively spared from the onslaught of infections and deaths, our nation’s scientists need to be part of the global effort to address this pandemic.…  Read more

There is something unusual about the initial—or innate—immune response to COVID-19 compared to usual influenza patterns. …  Read more

Severe COVID-19 infection presents as excessive lung inflammation, involving the build-up of cells and fluid in the lungs. This phenomenon, known as ARDS, restricts breathing and causes damage to the lungs. Severely affected patients will need ventilator assistance in intensive care.…  Read more

Sepsis is a hyper-acute inflammatory response leading to life-threatening organ dysfunction. Sepsis is usually caused by bacterial infections; however, the COVID-19 pandemic illustrates that hyper-acute inflammation can also be part of viral infections.…  Read more

Biotech company Noxopharm is seeking approval from the US FDA for a clinical trial in COVID-19 patients of an end-stage prostate cancer drug, following a discovery by Hudson Institute researchers that it could act as an anti-inflammatory.…  Read more

Hudson Institute has responded to the coronavirus outbreak (COVID-19) both scientifically and to protect the wellbeing of our staff and community.  Our world-leading scientists are applying their expertise in hyper-inflammation, to find ways to reduce the body’s overwhelming inflammatory response and acute respiratory distress that is leading to loss of lives from COVID-19. During this…  Read more

An existing cancer drug could potentially modify a severe hyper-inflammatory ‘storm’ associated with some conditions, which may include the COVID-19 virus, according to Hudson Institute researchers.…  Read more